fbpx

molecules of the month

BI 730357

Oral RORy nuclear receptor antagonist

on-going Ph. II for psoriasis (QD dosing)

50k cmpd high-conc. frag. screen + scaff. hop

ACS Med. Chem. Lett., Jan. 5, 2021

Boehringer Ingelheim, Ridgefield, CT

Chemical structure of molecule BI-730357
1 min read

The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last year in February and March. While most clinical RORγ modulators have discontinued development after reaching Ph. II, BI 730357’s Ph. II trial appears to be on-going.


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: